Compare SEAT & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEAT | ATYR |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | United States | United States |
| Employees | 768 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 69.2M |
| IPO Year | N/A | N/A |
| Metric | SEAT | ATYR |
|---|---|---|
| Price | $6.10 | $0.92 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 8 |
| Target Price | ★ $32.94 | $4.20 |
| AVG Volume (30 Days) | 95.5K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9,628.95 |
| Revenue Next Year | N/A | $156.94 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $0.64 |
| 52 Week High | $35.00 | $7.29 |
| Indicator | SEAT | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 50.02 |
| Support Level | $5.94 | $0.67 |
| Resistance Level | $7.84 | $1.09 |
| Average True Range (ATR) | 0.67 | 0.07 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 33.03 | 34.82 |
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.